Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 40 results for prostatic hyperplasia

  1. GreenLight XPS for treating benign prostatic hyperplasia (MTG74)

    Evidence-based recommendations on GreenLight XPS for benign prostatic hyperplasia.

    Medical technologies guidance
    Published
    29 November 2022
    View recommendations

    Sections for MTG74

  2. Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)

    NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...

    Technology appraisal guidance
    Published
    23 January 2013

    Sections for TA273

  3. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)

    Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.

    Medical technologies guidance
    Published
    4 May 2021
    View recommendations

    Sections for MTG58

  4. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia

    Awaiting development [GID-MT599] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  5. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)

    Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.

    Medical technologies guidance
    Published
    24 June 2020
    View recommendations

    Sections for MTG49

  6. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB315)

    NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .

    Medtech innovation briefing
    Published
    31 January 2023

  7. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG737)

    Evidence-based recommendations on prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves positioning a temporary implant in the urethra to increase the flow of urine.

    Interventional procedures guidance
    Published
    21 September 2022
    View recommendations

    Sections for IPG737

  8. iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)

    NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .

    Medtech innovation briefing
    Published
    21 September 2022

  9. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPG475)

    Evidence-based recommendations on insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. This involves pulling back the parts of the prostate that are pressing on the urethra so that it's no longer blocked.

    Interventional procedures guidance
    Published
    23 January 2014
    View recommendations

    Sections for IPG475

  10. Insights from the NHS: adoption of UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia at St Helens and Knowsley Teaching Hospital NHS Trust

    sexual function that can happen as a result of treatment for benign prostatic hyperplasia (BPH), the Urology team at the trust were...

    Shared learning
    Last updated
    27 January 2017

  11. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG611)

    Evidence-based recommendations on prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves blocking the blood vessels supplying the prostate with tiny plastic particles.

    Interventional procedures guidance
    Published
    25 April 2018
    View recommendations

    Sections for IPG611

  12. Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG770)

    Evidence-based recommendations on transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves injecting a high-speed jet of water into the prostate to destroy some of the prostate tissue and widen the urethra.

    Interventional procedures guidance
    Published
    14 September 2023
    View recommendations

    Sections for IPG770

  13. Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG625)

    Evidence-based recommendations on transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves using heated water vapour to destroy some of the prostate tissue.

    Interventional procedures guidance
    Published
    21 August 2018
    View recommendations

    Sections for IPG625

  14. The PLASMA system for transurethral resection and haemostasis of the prostate (MTG53)

    Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate.

    Medical technologies guidance
    Published
    6 January 2021
    View recommendations

    Sections for MTG53

  15. PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)

    NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .

    Medtech innovation briefing
    Published
    31 August 2021